I A Migunov

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Venous thromboembolism is the major cause of death and important health problem. Anticoagulants is the mainstay modality of VTE treatment and rivaroxaban was the first novel anticoagulant approved for VTE treatment and secondary prevention in Russia. Current study was designed to assess efficacy and safety of rivaroxaban from the first day of VTE treatment.(More)
  • 1